A Systematic Review of the Usage of Rotigotine During Early and Advanced Stage Parkinson's

Parkinson's disease (PD) is a prevalent neurodegenerative disorder that occurs in old age due to a decrease in dopamine, which causes nerve cell destruction. This disease is difficult to diagnose since its symptoms are similar to those of the aging process. Those with PD have impaired motor control and function, dyskinesia, and tremors. To treat PD, drugs that enhance the amount of dopamine given to the brain are administered to alleviate symptoms. This inquiry examines the prescription of rotigotine to achieve this objective. The primary objective of this review is to examine the usage of rotigotine in both the late and early stages of PD. The statistical model utilized in the review found that there was not a significant difference in the dosage of rotigotine prescribed to late and early-stage PD patients, however, there were some confounding variables that may have skewed this result; therefore, further research is necessary to validate or nullify this hypothesis.

Automated summary

Parkinson's disease (PD) is a prevalent neurodegenerative disorder caused by a decrease in dopamine, leading to nerve cell destruction. Diagnosing PD is challenging due to similar symptoms with aging. PD patients experience impaired motor control and function, dyskinesia, and tremors. Treatments involve administering drugs that increase dopamine in the brain. This study investigates the usage of rotigotine in both early and late stages of PD. The statistical model found no significant difference in rotigotine dosage between late and early-stage PD patients but acknowledges the need for further research to validate or nullify this hypothesis due to potential confounding variables.